Syncytin, envelope protein of human endogenous retrovirus (HERV): no longer 'fossil' in human genome.

Human endogenous retroviruses (HERVs) are 'fossil viruses' that resulted from stable integrations of exogenous retroviruses throughout evolution. HERVs are defective and do not produce infectious viral particles. However, some HERVs retain a limited coding capacity and produce retroviral transcripts and proteins, which function in human developmental process and various pathologies, including many cancers and neurological diseases. Recently, it has been reported that HERVs are differently expressed in COVID-19 disease caused by infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In this review, we discuss the molecular structure and function of HERV ENV proteins, particularly syncytins, and their conventional roles in human development and diseases, and potential involvement in COVID-19 regarding the newly reported mental symptoms. We also address COVID-19 vaccine-related infertility concerns arising from the similarity of syncytin with the spike protein of SARS-CoV-2, which have been proved invalid.

Introduction

Human endogenous retroviruses (HERVs) represent 8% of the human genome (Lander et al. 2001). HERVs are derived from germline infections by exogenous retroviruses early in the evolution of primates (Barbulescu et al. 1999). A complete HERV is approximately 9.5 kb in length and consists of four essential viral genes; gag, pro, pol, and env flanked by two long-terminal repeats (LTRs) (Griffiths 2001; Khodosevich et al. 2002; Balada et al. 2009; Kim and Shin 2020). LTRs can act as promoters to drive HERV genes and contain regulatory sequences, binding transcription factors (Durnaoglu et al. 2021; Ito et al. 2017). A majority of HERVs in human genome are disrupted along the evolutionary path, mostly found in heterochromatin, and suppressed by epigenetic silencing at steady state (Rowe and Trono 2011). Expression of HERVs is often elevated in various physiological and pathological conditions (Dolei et al. 2019; Durnaoglu et al. 2021). In cancers, for example, a specific HERV env gene is activated and plays a crucial role in inducing carcinogenesis in certain malignant tumors, including breast cancer, pancreatic cancer, germ cell tumors, leukemia, and Kaposi's sarcoma (Alcazer et al. 2020; Gao et al. 2021). Syncytin-1 and 2, ENV proteins of HERV-W and HERV-FRD, respectively, are expressed in the placenta and involved in trophoblast formation (Dupressoir et al. 2012). In addition, syncytin-1 expression is elevated in neuropathological disorders such as schizophrenia (SZ) and bipolar disorder (BD) while positively correlated with C-reactive protein (CRP) levels, an inflammation indicator (Perron et al. 2008; Wang et al. 2018). CRP is an acute-phase serum protein, and its level rises when there is inflammation in the body (Du Clos and Mold 2004). Several factors increase the CRP level, such as infectious or non-infectious acute and chronic conditions, trauma, sleep disturbances, and periodontal diseases (Nehring et al. 2021).

Coronavirus disease 2019 (COVID-19) is a highly contagious viral illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Lovato et al. 2020). Several symptoms include weakness, respiratory distress, muscle pain, sore throat, loss of taste and smell associated with the disease ranging from asymptomatic/mild symptoms to severe illness and even death. Although vaccination against SARS-CoV-2 helps protect from COVID-19, some people are hesitant to the vaccinations for a number of reasons, including a rumor that concerns a cross-activity of anti-SARS-CoV-2 spike protein syncytin-1 in the placenta. Also, some recent reports show the differentially expressed HERVs in COVID-19 patients, suggesting that HERVs may be involved in COVID-19 epidemiology (El-Shehawi et al. 2020; Kitsou et al. 2021; Marston et al. 2021). On the other hand, it has been reported that CRP level increases in serum from COVID-19 patients and positively correlates with disease severity (Chen et al. 2020; Luo et al. 2020). CRP is suggested as a factor contributing to the development of severe cases of COVID-19 by inducing the production of proinflammatory cytokines, apoptosis, and the inflammatory status (Mosquera-Sulbaran et al. 2021). In addition, CRP levels in COVID-19 patients with depression are higher than those without depression (Yuan et al. 2020; Lorkiewicz and Waszkiewicz 2021). Several meta-analyses have reported that patients with psychotic disorders have higher CRP levels than healthy individuals; however, the cause–effect relation is unclear (Miller et al. 2014; Osimo et al. 2021). There are also several cases of COVID-19 patients with elevated CRP levels, showing psychosis without a personal or family history (Ferrando et al. 2020; Smith et al. 2020; Łoś et al. 2021).

The review focuses on syncytins and CRP expression in mental disorders and the case reports with mental symptoms in COVID-19 patients. Furthermore, we summarize the scientific data, which confirms that there is no link between COVID-19 vaccines to problems related to pregnancy arising from the so-called similarity between syncytin and the spike protein of SARS-CoV-2 (Hillson et al. 2021; Kloc et al. 2021; Morris 2021; Rajak et al. 2021; Shimabukuro et al. 2021). Conversely, COVID-19 disease can hinder healthy fertility in both males and females (Jing et al. 2020; Shen et al. 2020; Cavalcante et al. 2021; Sharma et al. 2021; Vizheh et al. 2021). The insights from HERV activation in COVID-19 patients not only help understand the epidemiology of the pandemic with complicated symptoms, including mental disorders but also provide valuable information utilized in the development of therapeutic intervention of the viral disease.

Syncytins

Some envelope glycoproteins encoded by env genes of human endogenous retroviruses (HERV) are expressed in the human placenta and play a critical role in early human development (Petropoulos et al. 2016; Yabe et al. 2016; Okae et al. 2018; West et al. 2019; Roberts et al. 2021). Those placental ENVs contribute to placental syncytial structures; Therefore, they are named syncytins (Figure 1). While the ENV protein products of ERVW1, ERVFRD-1, ERVV-1, ERVV-2, ERVH48-1, ERVMER34-1, ERV3-1, and ERVK13-1 are all detected in placental trophoblasts, most studied are HERV-W1 ENV product, the first identified syncytin-1, and ERVFRD-1 ENV product, syncytin-2 (Blond et al. 2000; Sha et al. 2000; Gong et al. 2005). These two syncytins share a very similar molecular structure that mediates effective membrane fusion (Figures 1 and 2).

Figure 1.

Structure of syncytin-1. (A) 3D crystal structure images of trimeric syncytin-1 are created with iCn3D structure viewer (Wang et al. 2020). PDB ID: 5HA6 (doi:10.2210/pdb5HA6/pdb). (B) Schematic representation of syncytin-1 monomer describing the surface unit (SU) and transmembrane (TM) units. Crystalized region shown in (A) is described in pink ribbon. The receptor binding site (RBD) is located in SU, and binds to the hASCT2 receptor to trigger membrane fusion. One disulfide bond links SU and TM. Fusion peptide (cyan blue), transmembrane domain (orange), and the intracytoplasmic tail (yellow) are indicated. (C) Functional sites in syncytin-1 are highlighted. Amino acid residues forming heptad repeats (HR1 and HR2), immunosuppressive domain (ISD), CI binding site, CX(6)C motif, a disulfide bond and homotrimer interface are labeled.

Figure 2.

Syncytin family expressed in human trophoblast. Syncytin-1 and syncytin-2 are the env gene products of HERV-W and HERV-FRD, respectively. The coding genes are also known as ERVW-1 and ERVFRD-1, respectively. It has been shown that both syncytin-1 and -2 promote cell-cell fusion in placenta development. These two syncytins have all domains required for the fusion process; a fusion core made of heptad repeats (HR1 and HR2), CX(6)C motif, and homotrimerization interface. ERVV-1, ERVV-2, and ERV3-1 are little studied but are expressed in syncytiotrophoblast from early human embryos and in in vitro differentiated placental trophoblast (TB). ERVRH48-1 is known as suppressyn or SUPYN, expressed in unfused cytotrophoblast cells. SUPYN inhibits TB fusion in vitro, because it lacks all major domains and presumably acts as a competitor for other syncytins. ERVMER34-1 may inhibit promote fusion, too. ERVK13-1 encodes a long non-coding RNA transcript of unknown function. The domains are retrieved from NCBI's Conserved Domain Database (CDD) (Marchler-Bauer et al. 2017).

Syncytin-1

Syncytin-1 is a protein consisting of 538 amino acids, and HERV-W1 coding syncytin-1 is located at 7q21.2 of human chromosome 7. Syncytin-1 contains an N-terminal signal peptide of amino acids number 1 to 20 (aa 1-20), a surface unit (SU, aa 21-317), and a transmembrane unit (TM, aa 318-538). SU and TM contain functional domains for the protein’s physiological activities: receptor-binding domain (RBD), fusion peptide (FP), the fusion core N- and C-terminal heptad repeats (HR1 and HR2, respectively), immunosuppressive domain (ISD), transmembrane domain (TD), and intracytoplasmic tail (CYT) (Gimenez and Mallet 2008; Grandi and Tramontano 2018) (Figure 1).

Syncytin-1 is synthesized as a glycosylated gPr73 precursor that forms a homotrimeric structure (Figure 1). Syncytin-1 precursor is cleaved into two mature proteins: the gp50 SU and the gp24 TM (Gimenez and Mallet 2008). The cleavage takes place at the SU/TM junction, at a furin cleavage site of RNKR. Through a disulfide bond, SU and TM are covalently bonded and reach the cellular membrane. SU is in charge of recognizing and binding to cell receptors to initiate membrane fusion. The hydrophobic FP and fusion core consisting of HR1 and HR2 are presented in TM. HRs are also associated with homotrimerization. TM contains immunosuppressive domain (ISD), which is located inside HR2 and ends in the CYT. The CYT of the TM, FP, and fusion core consisted of HR1 and HR2 are all essential for the fusion process. ISD domain is suggested to confer syncytin-1 a critical role in fetal-maternal tolerance during pregnancy (Lokossou et al. 2014).

Syncytin-1 is highly fusogenic and actively involves trophoblast cell fusion and differentiation, thereby functioning in human placental morphogenesis critical for normal placental function (Blond et al. 2000; Frendo et al. 2003). Human placenta contains specialized trophoblast cells crucial for embryo implantation and placental development (Benirschke et al. 2012). At the early gestation stage, mononuclear cytotrophoblasts differentiate and fuse into a continuous layer of multinucleated syncytiotrophoblast. The syncytiotrophoblast layer is the site of various placental functions, including oxygen transport, nutrient exchange, immune tolerance, and the synthesis of hormones required for fetal growth and development. The fusogenic activity of syncytin-1 is activated upon interaction with the type D mammalian retrovirus receptor (Blond et al. 2000), referred to as hASCT-1/-2 (human sodium-dependent neutral amino acid transporter type 2) (Lavillette et al. 2002).

Syncytin-1 mRNA and protein levels are higher in the brain tissue from multiple sclerosis (MS) patients than in that from normal individuals. Syncytin-1 is specifically expressed in astrocytes, glial cells, and activated macrophages of MS lesions (Antony et al. 2004). In vitro expression of syncytin-1 induces the production of proinflammatory factors such as iNOS, IL-1β, and redox reactants in human fetal astrocytes (HFAs). Syncytin-1-expressing astrocytes are cytotoxic to oligodendrocytes, releasing redox reactants. In a mouse MS model, syncytin-1 mediates neuroinflammation and cell death of oligodendrocytes, which are prevented by antioxidant ferulic acid.

Also, syncytin-1 is implicated in several neural diseases. Syncytin-1 is highly expressed in activated immune cells in MS, but even higher during infections (Garcia-Montojo et al. 2020). Flow cytometry analysis of peripheral blood mononuclear cells (PBMC) from healthy donors, MS patients in relapse or remission, and patients with acute infections reveal that syncytin-1 is elevated in monocytes during MS relapses or acute infections. After stimulation with LPS, activated T and B lymphocytes and natural killer cells (NKs) increase expression levels of syncytin-1. The study suggests that syncytin-1 plays a critical role in the early stages of immune cell activation and may contribute to MS pathogenesis. In addition, overexpression of syncytin-1 in microglia induces the expression of inducible nitric oxide synthase (iNOS) and results in increased NO production, enhancing microglial migration (Xiao et al. 2017).

Syncytin-1 expression is elevated in the serum sample of patients with SZ and BD compared to healthy subjects (Perron et al. 2008; Perron et al. 2012). The level of CRP inflammation biomarker is correlated with syncytin-1 level. These results suggest that syncytin-1 plays a role in inflammatory regulation in neuropsychological diseases. It is reported that syncytin-1 triggers CRP activation via TLR3 signal cascade in glial cells (Wang et al. 2018). Overexpression of syncytin-1 increases CRP, TLR3, and IL-6 in both human microglia and astrocytes. Syncytin-1 induces expression of CRP and IL-6, but the induced expression is not observed in the lack of TLR3. Furthermore, syncytin-1 activates innate immunity by inducing the secretion of major proinflammatory cytokines such as IL-1β, IL-6, or TNF-α via CD14 /TLR4 in human monocytes (Rolland et al. 2006). Therefore, the tight association between the expression level of syncytin-1 and inflammatory events in glial cells may be involved in the etiology and pathology of psychotic diseases.

Syncytin-1 is also implicated in various types of cancers such as endometrial cancer, breast cancer, leukemia, urothelial cell carcinoma and human hepatocellular carcinoma, and enhances the cell proliferation, metastasis, and tumorigenicity (Yu et al. 2013; Sun et al. 2017; Chignola et al. 2019; Liu et al. 2018; Zhou et al. 2021). Syncytin-1 expression is associated with DNA methylation in the 5′LTR of the syncytin-1 gene in several cancers (Huang et al. 2014). In pancreatic cancer (Lu et al. 2015), decreased syncytin-1 expression is correlated with increased DNA methylation in the 5′ LTR region of syncytin-1 promoter, and syncytin-1 expression is reactivated when methylation levels in 5′LTR are reduced (Huang et al. 2014). Therefore, epigenetic changes affect the expression of syncytin-1, thereby participating in cancer development.

Syncytin-2 in comparison with syncytin-1

Syncytin-2 is an envelope protein of the human endogenous retrovirus family HERV-FRD (Blaise et al. 2003; Grandi and Tramontano 2018). ERVFRD-1 encoding syncytin-2 is located at 6p24.1 of human chromosome 6. Syncytin-2 has all functional domains found in syncytin-1; SP (aa 1-15), SU (aa 16-350), and TM (aa 351-538), in which RBD, FP, HR1 HR2, ISD, TD, and CYT reside.

Syncytin-2 has been associated with one receptor, the major facilitator superfamily domain containing 2a (MFSD2a), a transporter for the essential omega-3 fatty acid (Nguyen et al. 2014). Like syncytin-1, syncytin-2 is also a fusogenic protein required for functional placental syncytia (Chang et al. 2004). While syncytin-1 is strongly expressed in villous syncytiotrophoblast, mainly in the basal membrane, but weakly in villous cytotrophoblasts, syncytin-2 is expressed in villous cytotrophoblasts (Roberts et al. 2021). Syncytin-2 is highly correlated with the degree of severity of preeclampsia (PE) (Vargas et al. 2011), a placental pathology characterized by maternal arterial hypertension, proteinuria, and organ dysfunction, in contrast to syncytin-1 in lesser degree (Bokslag et al. 2016). Both sequences of syncytin-1 and syncytin-2 harbor regions, which are highly similar to the conserved retroviral immunosuppressive domain (ISD) (Cianciolo et al. 1985; Kristensen and Christensen 2021). Syncytin-1 and syncytin-2 may be immunosuppressive via their association with placental exosomes (Tolosa et al. 2012; Lokossou et al. 2020). Peripheral blood mononuclear cells (PBMCs) cultured in the presence of syncytin-1-ISD then stimulated with lipopolysaccharides (LPS)/ phytohaemagglutinin (PHA) significantly reduces the production of the Th1 cytokines such as TNF-α and IFN-γ as well as the chemokine, CXCL1 (Park et al. 2020). Similarly, Jurkat cells were cultured with either syncytin-2-ISD region or trophoblast-derived exosomes and then stimulated with activating agents, phorbol 12-myristate 13-acetate (PMA)/ionomycin. Quantification analyses showed that induced Th1 cytokines, such as TNF-α, IFN-γ, and IL-2, were severely reduced. Thus, it is suggested that syncytin-1 and syncytin-2 contribute to exosome-mediated immunosuppression, reducing Th1 cytokine production in PBMCs.

HERVs in human diseases

HERVs are implicated in various diseases, including some psychiatric conditions such as schizophrenia (SZ) and bipolar disorder (BD) and COVID-19, a viral infectious pandemic disease whose patients commonly suffer from psychological distress. Especially, the expression level of syncytin-1, the product of HERV-W1, is often changed in these illnesses and associated with those of inflammatory markers.

Syncytin-1 in psychiatric diseases

Retroviral RNA of HERV-W family is detected in the cell-free cerebrospinal fluids (CSFs) of 10 of 35 individuals with recent-onset SZ or schizoaffective disorder but not in the CSFs of 22 individuals with noninflammatory neurological diseases or from 30 individuals with no neurological or psychiatric diseases (Karlsson et al. 2001). Increased transcription of HERV-W family RNA is found in the brain tissues from postmortem individuals with SZ compared to postmortem brain tissues from individuals without psychiatric diseases.

In a study done with 136 patients, 91 with BD, 45 with SZ, and 73 healthy controls, syncytin-1 transcription level is higher in patients with BD and SZ compared to healthy controls (Perron et al. 2012). In BD patients, the transcription level of syncytin-1 is also higher than in the patients with SZ. Syncytin-1 expression is detected in 23 of 49 patients with SZ, but only in 1 of 30 healthy controls (Perron et al. 2008). Syncytin-1 transcripts are detected in the plasma samples of 42 out of 118 patients with recent-onset SZ, and none is detected in 106 controls (Huang et al. 2011). Quantitative RT–PCR (qRT-PCR) showed 35.59% increased retroviral activity in sera of SZ patients compared to 2.83% activity in normal individuals. Also, overexpression of syncytin-1 in human U251 glioma cells increases the expression of brain-derived neurotrophic factor (BDNF), neurotrophic tyrosine kinase receptor type (NTRK2), and dopamine receptor D3 (DRD3) which contribute to the pathogenesis of the recent-onset SZ at both the mRNA and the protein levels determined by qRT- PCR and western blot (Lewis and Lieberman 2000; Woo et al. 2020). The luciferase assay reveals that syncytin-1 significantly activates BDNF promoter activity in human U251 glioma cells. Therefore, the data suggest that syncytin-1 increases the promoter activation of BDNF, NTRK2, and DRD3 and increases the expression of these genes in neuroglia cells.

SZ patients and patients with other neurological disorders such as Alzheimer's disease display calcium imbalance (Berridge 2012). Syncytin-1 induces Ca2+ influx in human neuroblastoma cells and upregulates the expression of transient receptor potential channel C3 (TRPC3) via directly regulating its expression or downregulating disrupted-in-schizophrenia 1 (DISC1), a susceptibility factor for SZ, which is a scaffold protein interacting with various proteins to regulate synaptic processes and dopamine signaling (Chen et al. 2019; Kim et al. 2020).

HERVs and COVID-19

COVID-19 patients exhibit increased prevalence of psychological conditions and HERVs are often highly expressed in people with COVID-19 infection. Therefore, HEVRs might contribute to the process of viral penetration and the onset of symptoms in COVID-19 disease.

Based on a questionnaire with 205 participants regarding psychological distress, COVID-19 patients show a predominantly increased prevalence of depression (Zhang et al. 2020). Another study shows that 96.2% out of 714 hospitalized but clinically stable COVID-19 patients suffered from significant post-traumatic stress disorder (PTSD) symptoms before discharge (Bo et al. 2021). Several COVID-19 patients with no previous psychiatric history experience psychotic symptoms characterized by thoughts of reference and structured delusional beliefs as in primary psychosis conditions (Rentero et al. 2020). Some patients also showed acute delirium, and those were the only patients who also suffered from hallucinations. Another case of symptomatic COVID-19-related psychosis in a 36-year-old patient with no personal or family history of mental illness is reported (Smith et al. 2020). The patient shows an acute and rapidly progressive change in behavior characterized by reduced sleep and delusions. Antipsychotics and benzodiazepines helped to improve psychotic symptoms, and further improvement was seen with the resolution of COVID-19 symptoms.

A follow-up study after 6 months of diagnosis of 182 COVID-19 patients show that 91.2% of the patients had psychiatric symptoms, such as poor sleep (64.8%), PTSD (28.6%), somatization (41.8%), obsessive-compulsive (19.8%), depression (11.5%), anxiety (28%), phobic-anxiety (24.2%) and psychoticism (17.6%) (Ahmed et al. 2021). The critical group regarding the severity of COVID-19 infection presents the highest percentages of PTSD, anxiety, and psychosis. The non-severe group had the least CRP level. The study among a total of 27 patients (11 mild cases, 12 moderate cases, 2 severe cases, and 2 critical cases) revealed CRP levels positively correlated with the lung lesion and disease severity (Wang 2020). CRP levels and the diameter of the largest lung lesion increased as the disease progressed.

Another case study also showed that 3 patients who did not show any physical symptoms for COVID-19 but displayed new-onset psychotic symptoms including anxiety, suicidal ideation, agitation, suspiciousness, auditory hallucinations, paranoid and persecutory delusions (Zhang et al. 2019; Ferrando et al. 2020). They were all further tested positive for COVID-19 even though no respiratory or gastrointestinal symptoms, and vital signs, complete blood count, comprehensive metabolic panel, chest x-ray, and brain computed tomography (CT) scan were normal. However, all patients had increased inflammatory markers, notably CRP. CRP involves in triggering schizophreniform psychosis, which is similar to SZ, but usually lasts for less than 6 months (Miller et al. 2014). Thus, there might be a possible virus-associated inflammatory trigger because of elevated CRP level in SARS-CoV-2 infection in these COVID-19 patients.

HERVs may play a role in SARS-CoV-2 infection and COVID-19 symptoms (El-Shehawi et al. 2020). HERVs or their viral products might promote the infection and penetrance of the virus to human cells, or HERVs may produce proteins that regulate the translation start for the ribosome changing the pattern of COVID-19 ORFs in different human hosts; thus the severity and course of the COVID-19 infection would differ.

According to a transcriptome analysis, the expression of HERV-FRD, HERV-H, HERV-W, HERV-L, HERV-I, HERV-K (HML-5), HERV-K (HML-3) and HERV-K (HML-1) is significantly upregulated in bronchoalveolar lavage fluid (BALF) of COVID-19 patients compared to that in BALF of healthy individuals but not in the peripheral blood monocytes (PBMCs) (Kitsou et al. 2021). HERV-FRD is the most highly upregulated family among other HERVs. Another recent study supports the finding of upregulated HERVs in BALF of COVID-19 patients (Marston et al. 2021). Both syncytin-1 and syncytin-2 are highly expressed in BALF of COVID-19 patients, but none are detected in PBMCs (Charvet et al. 2021). SARS-CoV-2 activates syncytin-1 and HERV-K env transcription in vitro through the interaction between spike proteins and ACE2 on T lymphocytes.

Syncytin-1 is highly expressed in the leukocytes of 30 hospitalized COVID-19 patients with a wide range of severity of illnesses (Balestrieri et al. 2021; Garcia-Montojo and Nath 2021). The expression of syncytin-1 is correlated with the inflammatory markers and the severity of illness in COVID-19 patients. A study in pediatric COVID-19 patients shows that the expression of HERVs in children with mild symptoms is higher than in children with severe symptoms or with multisystem inflammatory syndrome MIS-C (Tovo et al. 2021). Patients are categorized into four groups; 36 children with mild/moderate symptoms, 17 children with severe symptoms and 11 children with MIS-C. Transcriptional levels of pol genes of HERV-H, HERV-K, and HERV-W, and of env genes of syncytin-1, syncytin-2, and MSRV are varied among four groups. Children with mild symptoms have the highest expression for HERV-H-pol, HERV-K-pol, syncytin-1, and syncytin-2. In contrast, children with severe symptoms show significantly lower HERV-W-pol and MSRV-env than the control group, but a comparable expression of HERV-H-pol and HERV-K-pol to the control. The correlation between HERVs and SARS-CoV-2-infected children suggests that HERVs might involve in the infection process.

Infertility concerns: now all over

During the COVID-19 pandemic, there is still high vaccine hesitancy among people. In addition to safety concerns handling and administering vaccines, there is an opinion that it is unnecessary to vaccinate against COVID-19 because the disease is considered not life-threatening. Also, some lack trust on the administration and doubts about the efficiency of vaccination. Above all, some scientists warned that vaccination might cause infertility in women at the early stage of vaccine development (Dror et al. 2020; Troiano and Nardi 2021). Hesitancy regarding vaccination is higher among the younger and female population, who might have been influenced by possible infertility associated with vaccines, which is now turned out to be out of concern. The false concept that COVID-19 vaccines might cause infertility emerged from a claim that antibodies against products of COVID-19 vaccines could attack the placenta since these antibodies of SARS-CoV-2 spike protein can cross-react with the human placental protein syncytin-1, the ENV protein of HERV-W (Male 2021). However, several fertility and obstetric organizations released statements that there is no evidence linking the vaccine to infertility (Schaler and Wingfield 2021).

First of all, the BLAST comparison between the amino acid sequences of human syncytin-1 (538aa) and SARS-CoV-2 spike protein (1273aa) indicates no homology between these two proteins; They are similar in only one 5-amino acid stretches, VVLQN for syncytin-1 and VVNQN for the spike protein, only two 2-amino acids identities (VV and QN). Considering the lack of homology between these two proteins, it is very unlikely that any antibodies raised against SARS-CoV-2 spike protein cross-react with endogenous human syncytin-1 (Kloc et al. 2021). Scientific studies show no cross-reactivity of anti-spike protein antibodies with syncytin-1 (Prasad et al. 2021). In the study, a stable HEK293 cell line expressing syncytin-1 on the cell surface is generated and anti-spike protein antibody activity was tested by an in-cell ELISA. None of the ten monoclonal antibodies tested bind to syncytin-1. Although the amount of anti-spike protein was increased in the plasma of vaccinated individuals, any cross-reactivity was detected with syncytin-1. In addition, no anti-syncytin-1 antibodies were detected in the plasma of COVID-19 patients. These data clearly show that there is no cross-reactivity between antibodies against a SARS-CoV-2 spike protein and endogenous syncytin-1.

Expectedly, a cohort study conducted in 3,958 pregnant women shows no risk of increased miscarriage in women vaccinated in early pregnancy, compared to the general female population (Shimabukuro et al. 2021). Also, a clinical study conducted in three countries of UK, Brazil, and South Africa indicates that the adenovirus-based vector COVID-19 vaccine shows no increased risk of miscarriage and reduced fertility in women who received the vaccine before pregnancy. Among 9755 participants, 121 pregnancies were reported during trials (Hillson et al. 2021). The fertility outcome analysis set included 93 pregnant women, 50 of who received the COVID-19 vaccine, and 43 of whom received the control vaccine. No evidence was found for a relation between reduced fertility and vaccination COVID-19 vaccine. The pregnancy outcome analysis set included 72 of whom received the COVID-19 vaccine, and 35 received the control vaccine. Global clinical trials of COVID-19 vaccine found no increased risk of miscarriage and instances of stillbirth in women vaccinated before pregnancy, compared with women who received the control vaccine (Hillson et al. 2021). Finally, a study using frozen embryo transfer (FET) in women shows no difference in embryo implantation rates or early pregnancy development between SARS-CoV-2 vaccine seropositive, infection seropositive, and seronegative women (Morris 2021). Thus, no evidence is found regarding COVID-19 vaccines resulting in female sterility.

Conclusion

HERVs have been participating in human evolution. Human development requires HERV ENV proteins to build a highly elaborate placenta. When dysregulated, those proteins unbalance cellular activities to aggravate human diseases such as cancers and mental illnesses. Recent studies indicate that the essential HERV ENV proteins may be involved in developing the psychotic and cognitive symptoms of COVID-19 disease. Based on clear scientific evidence, the speculation regarding COVID-19 vaccinations causing infertility due to a misunderstanding of viral protein structure has been proved wrong. HERV activities in COVID-19 disease strongly suggest that the ancient relics in the human genome play a significant role in human evolution even in the unprecedented pandemic of COVID-19.